Literature DB >> 23777765

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

Sanja Stevanovic1, Cornelis A M van Bergen, Simone A P van Luxemburg-Heijs, Boris van der Zouwen, Ekaterina S Jordanova, Alwine B Kruisselbrink, Marian van de Meent, Jessica C Harskamp, Frans H J Claas, Erik W A Marijt, Jaap Jan Zwaginga, Constantijn J M Halkes, Inge Jedema, Marieke Griffioen, J H Frederik Falkenburg.   

Abstract

CD8+ T cell-depleted (TCD) donor lymphocyte infusion (DLI) after TCD allogeneic hematopoietic stem cell transplantation (alloSCT) has been associated with a reduced risk of graft-versus-host disease (GVHD) while preserving conversion to donor hematopoiesis and antitumor immunity, providing a rationale for exploring CD4+ T cell-based immunotherapy for hematologic malignancies. Here, we analyzed the clinical course and specificity of T cell immune responses in 2 patients with acute myeloid leukemia (AML) who converted to full-donor chimerism but developed severe acute GVHD after prophylactic CD4+ DLI after 10/10-HLA-matched, but HLA-DPB1-mismatched TCD-alloSCT. Clonal analysis of activated T cells isolated during GVHD demonstrated allo-reactivity exerted by CD4+ T cells directed against patient-mismatched HLA-DPB1 molecules on hematopoietic cells and skin-derived fibroblasts only when cultured under inflammatory conditions. At the time of CD4+ DLI, both patients contained residual patient-derived T cells, including cytomegalovirus (CMV)-specific T cells as a result of CMV reactivations. Once activated by CMV antigens, these CMV-specific T cells could stimulate HLA-DPB1-specific CD4+ T cells, which in turn could target nonhematopoietic tissues in GVHD. In conclusion, our data demonstrate that GVHD after HLA-DPB1-mismatched CD4+ DLI can be mediated by allo-reactive HLA-DPB1-directed CD4+ T cells and that ongoing viral infections inducing HLA class II expression on nonhematopoietic cells may increase the likelihood of GVHD development. This trial is registered at http://www.controlled-trials.com/ISRCTN51398568/LUMC as #51398568.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23777765     DOI: 10.1182/blood-2012-12-470872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

Authors:  Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

Review 2.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 3.  The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

4.  HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.

Authors:  W Herr; Y Eichinger; J Beshay; A Bloetz; S Vatter; C Mirbeth; E Distler; U F Hartwig; S Thomas
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

Review 5.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

Review 6.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.

Authors:  Hideki Nakasone; Lu Tian; Bita Sahaf; Takakazu Kawase; Kelsi Schoenrock; Spenser Perloff; Christine E Ryan; Jed Paul; Rakesh Popli; Fang Wu; Joanne M Otani; John Coller; Edus H Warren; David B Miklos
Journal:  Blood       Date:  2015-03-12       Impact factor: 22.113

8.  MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Authors:  Motoko Koyama; Pamela Mukhopadhyay; Iona S Schuster; Andrea S Henden; Jan Hülsdünker; Antiopi Varelias; Marie Vetizou; Rachel D Kuns; Renee J Robb; Ping Zhang; Bruce R Blazar; Ranjeny Thomas; Jakob Begun; Nicola Waddell; Giorgio Trinchieri; Robert Zeiser; Andrew D Clouston; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Immunity       Date:  2019-09-18       Impact factor: 31.745

Review 9.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

Review 10.  New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.

Authors:  X Chang; X Zang; C Q Xia
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.